Document is current

Article History

Received: 11 August 2025

Accepted: 14 August 2025

First Online: 11 September 2025

Conflict of interest

: A. Ilhan-Mutlu: Participation in advisory boards organized by MSD, Servier, Daiichi Sankyo, BMS, Amgen and Astellas, lecture honoraria from Eli Lilly, Servier, BMS, MSD, Astellas, Astra Zeneca, BeiGene and Daiichi Sankyo, consulting for Astellas, MSD, Amgen, Astra Zeneca, BeiGene, and Roche, travel support (all via institutional nomination) from BMS, Roche, Eli Lilly, Daiichi Sankyo and BeiGene. F. Lordick: Personal fees from Amgen, personal fees from Astellas, personal fees and scientific grants from Astra Zeneca, personal fees from Art Tempi, personal fees and grants from Beigene, personal fees and scientific grants from BMS, personal fees from Boehringer Ingelheim, personal fees and scientific grants from Daiichi Sankyo, personal fees from Eli Lilly, personal fees from Elsevier, personal fees and grants from Gilead personal fees from Iomedico, personal fees from Incyte, personal fees from MedUpdate, personal fees from Merck Serono, personal fees from MSD, personal fees from PAGE, personal fees from Roche, personal fees from Servier, personal fees from Springer Nature, personal fees from StreamedUp!, personal fees from Servier, outside the submitted work. E. Wöll: Participation on advisory boards organized by: Astra Zeneca, Astella Pharma, Beigene, BMS, Daiichi Sankyo Austria, Eli Lilly, GSK, Gilead, Janssen Cilag, Jazz Pharma, Johnson&Johnson, MSD, Merck, Novartis, Eisai, Roche, Servier, Stemline, Takeda. Lecture honoraria from Amgen, Astellas, Astra Zeneca, BMS, Celgen, Ebewe, Eli Lilly, Eisai, Janssen Cilag, Merck, MSD, Pierre Fabre, Pfizer, Ratiopharm, Roche, Sanofi Aventis, Takeda, Daiichi Sankyo Austria.